Table 1 |
|||
|
Characteristics of Participants |
|||
|
Total |
Phase 2 - treatment |
Phase 2 - placebo |
|
|
|
|||
|
Total Participants |
77 |
26 |
15 |
|
Male |
69 |
24 |
14 |
|
Female |
8 |
2 |
1 |
|
Age (years) |
6.3 |
6.7 |
6.5 |
|
Diagnosis |
95% autism, 3% PDD/NOS, 3% Asperger's |
96% Autism, 4% Aspergers |
100% Autism |
|
|
|||
|
Adams et al. BMC Clinical Pharmacology 2009 9:16 doi:10.1186/1472-6904-9-16 |
|||
